Influenza Vaccine Post Allogeneic Transplant
Hematopoietic Stem Cell TransplantHematologic MalignancyStudy Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine doses one month apart. In addition, a cohort of healthy adult volunteers will be recruited as controls to confirm immune response to a single influenza vaccine.
Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)
InfluenzaThe purpose of the study is to get a better understanding of the natural and adaptive immune response to the flu virus and to compare the immune cell responses to FDA-licensed flu vaccines in nasal mucosal cells and in blood.
T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012
InfluenzaThis study will investigate markers, mechanisms and define general predictors for immunological health by comparing influenza vaccine responses in monozygotic and dizygotic twins.
Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)
InfluenzaThe purpose of the study is to investigate and compare the human immune response in epithelial cells of the nasopharyngeal mucosa and in blood to live, attenuated influenza vaccine (LAIV) in adults and in children.
Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates in New York...
Reminder System for Influenza VaccinesDespite U.S. guidelines for influenza vaccination of all children starting at age 6 months, only about half of children are vaccinated annually, leading to substantial influenza disease in children and spread of disease to adults. A major barrier is that families are not reminded about the need for their children to receive influenza vaccination. The investigators will evaluate the impact of patient reminder/recall performed by state immunization information systems to improve influenza vaccination rates by using three clinical trials in two states. The investigators will assess effectiveness and cost-effectiveness of phone reminder/recall on improving influenza vaccination rates. The investigators will disseminate the state immunization information system-based reminder/recall system to all states for use for seasonal and pandemic influenza vaccinations with the goal of lowering influenza morbidity.
Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department
Respiratory Tract InfectionsInfluenza2 moreThis is a randomized clinical trial to assess the effect of rapid, near point-of-care testing for multiple common respiratory viruses and bacteria on antibiotic and anti-influenza medication use in emergency department (ED) patients with symptoms of influenza-like illness (ILI) and/or upper respiratory infection (URI).
Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following...
InfluenzaThe purpose is to investigate B-cell response to the trivalent Influenza Vaccine (TIV) in healthy young adults by vaccinating participants and obtaining blood samples at designated time points before and after vaccination.
Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza...
Prevention of InfluenzaThis clinical fase IV study, using the administration of a single dose of a quadrivalent, inactivated, split influenza virus vaccine as biological intervention will mirror a study conducted at Imperial College, London, UK that will use a challenge with live virus as intervention. Comparison of the clinical observations and laboratory measurements generated in both studies will inform us about the similarities and differences in innate and adaptive immune responses elicited by both types of exposure to influenza virus antigen(s).
Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model
H1N1 Influenza Healthy VolunteersBackground: - Researchers want to see if a new drug reduces flu disease in people treated with this drug versus a placebo. The drug has an antibody that may help the immune system fight the flu. Placebo is only sugar and water. All participants will get the flu virus. They may or may not develop flu symptoms. Objective: - To see if the drug CR6261 reduces flu disease in people treated with this drug versus a placebo. Eligibility: - Healthy nonsmokers ages 18 45. Design: Participants will be screened under a separate protocol. Participants must use contraception or abstinence for several weeks before and after the study. They must have no alcohol for 1 day before each visit. Any medicine must be approved by the study doctor until after follow-up. Participants will stay in a hospital isolation unit for at least 10 days. They will have: Medical history Physical exam Blood and urine tests Heart and lung test Tests for drugs and alcohol Throughout their stay, participants will: Be closely watched by a medical team Have nasal washes and swabs several times a day Participants will have the flu virus sprayed in each nostril. The next day, participants will get either study drug or placebo through a soft plastic tube placed in a vein by needle. It will take 2 hours. They will not know which they get. Participants can go home after 10 days if they test negative for the flu 2 days in a row. Participants will have daily questionnaires at home and 2 follow-up visits over 2 months.
Assessment of Wearable Sensors During Experimental Human Influenza Infection (Sigma Plus)
Influenza A H3N2The aim of the study is to investigate disease in volunteers deliberately infected with influenza A(H3N2), including biological markers of inflammation and immune response, and changes in physiological parameters including heart rate, respiratory rate, physical activity, oxygen saturation and electrocardiographic data during the onset of influenza infection. Ultimately, this may lead to prediction of symptomatic disease at an earlier stage to allow more effective interventions. The experimental medicine study design will involve human influenza infection challenge, whereby volunteers will be inoculated with influenza virus and monitored in hospital for 10 days as they develop and get better from flu. Continuously-monitoring wearable physiological sensors will be given to the participants 7 days before this and worn continuously until the end of the flu infection.